Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03951116 · ClinicalTrials.gov registry record · Phase 1

Study of FCN-437c in Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumor, Adult, sponsored by Fochon Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
3
Study locations

NCT03951116: Completed Phase 1 study of Solid Tumor, Adult, sponsored by Fochon Pharmaceuticals.

NCT03951116 is a Phase 1 study of Solid Tumor, Adult that has completed, run by Fochon Pharmaceuticals. The registered enrollment target is 22 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03951116, a Phase 1 study of Solid Tumor, Adult, has completed, sponsored by Fochon Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
3
Study locations

Study Summary

This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.

Primary Outcome

Incidence of untoward medical occurrences (adverse event = AE) in a participant who received study drug. Adverse events will be evaluated by dosing cohort and recorded according to NCI CTCAEv5 Common Toxicity Criteria.

Conditions Studied

Solid Tumor, Adult

Interventions

  • DRUG FCN-437

Study Locations (3)

California

  • City of Hope National Medical Center - Duarte

Tennessee

  • Sarah Cannon Research Institute at Tennessee Oncology - Nashville

Texas

  • South Texas Accelerated Research Therapeutics (START) - San Antonio

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2019-06-25
Est. Completion 2021-12-08
Phase Phase 1
Fochon Pharmaceuticals

1 total trials

What the finished NCT03951116 record still lists

NCT03951116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which FCN-437 is the first listed.

NCT03951116 reports a single indexed study location in California, Tennessee, Texas.

Frequently Asked Questions

What is clinical trial NCT03951116 about?

NCT03951116 is a clinical study titled "Study of FCN-437c in Patients With Advanced Solid Tumors". This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.

What is the current status of trial NCT03951116?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-06-25. Estimated completion is 2021-12-08.

What conditions does trial NCT03951116 study?

This clinical trial studies the following conditions: Solid Tumor, Adult.

What interventions are being tested in trial NCT03951116?

The interventions under investigation include: FCN-437 (DRUG).

Who is sponsoring clinical trial NCT03951116?

This trial is sponsored by Fochon Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03951116 being conducted?

This trial has 3 study locations across California, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03951116's enrollment target sits among peer trials

22 71st of 72 higher than 2 of 72 other Solid Tumor, Adult trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03951116, the US trial registry maintained by the National Library of Medicine. NCT03951116 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.